UTRxMYCN M1-14 Nets FDA Dual Designations in Soft Tissue Sarcoma

The FDA has granted orphan drug designation to 3′UTRMYCN M1-14 (UTRxMYCN M1-14), an investigational RNA therapeutic directed against MYCN, for the treatment of patients with soft tissue sarcoma, including rhabdomyosarcoma.¹ The agency also granted rare pediatric disease designation to the agent for the treatment of rhabdomyosarcoma.

The designations were supported by preclinical findings. In MYCN-driven rhabdomyosarcoma, including fusion-positive disease, UTRxMYCN M1-14 produced dose-dependent MYCN inhibition, tumor inhibition, inhibition of liver and lung metastases, and it was also reported that the agent was safe. UTR Therapeutics described UTRxMYCN M1-14 as clinical trial–ready but did not disclose a timeline for a first-in-human study.

"The orphan drug and rare pediatric disease designations granted to UTRxMYCN M1-14 by the FDA validate the potential of UTRxMYCN M1-14 to address several aggressive sarcomas that represent serious unmet needs in the U.S. and worldwide," said David T. Asuzu, MD, chief medical officer of UTR Therapeutics, in the news release.

What is the mechanism of action of UTRxMYCN M1-14?

MYCN is a basic helix-loop-helix transcription factor in the MYC superfamily, since it is intrinsically disordered and lacks a binding pocket. MYCN is an oncogenic driver of aggressive soft tissue sarcoma, including fusion-positive rhabdomyosarcoma. No approved therapies directly target MYCN.

UTRxMYCN M1-14 is designed to act at the level of oncogenic mRNA. The agent overwrites endogenous oncogenic MYCN mRNA messages and marks the transcript for degradation through the nonsense-mediated decay pathway, a process the company says gets rid of diseased mRNA while preserving healthy mRNA.

What are the other recent regulatory developments in soft tissue sarcoma?

Notably, in September 2026, the FDA granted orphan drug designation to SOT106, an investigational antibody-drug conjugate (ADC), for soft tissue sarcoma and fast track designation to the agent for osteosarcoma.² With these additions, SOT106 holds both designations in both indications, having previously received orphan drug designation for osteosarcoma in June 2026 and fast track designation for soft tissue sarcoma in August 2026.³

Similar to UTRxMYCN M1-14, SOT106 has not entered clinical testing; its designations were supported by target biology and preclinical findings, including antitumor activity in of osteosarcoma and soft tissue sarcoma. First-in-human trials of SOT106 are expected to be initiated later in 2026.²

SOT106 pairs a leucine-rich repeat-containing 15 (LRRC15)–directed antibody with the microtubule-disrupting payload monomethyl auristatin E (MMAE) via site-specific conjugation. LRRC15 is expressed on malignant cells and in the tumor stroma of mesenchymal cancers, including a broad subset of sarcomas, with limited expression in normal adult tissue.

In gastrointestinal stromal tumors (GIST), the FDA accepted a new drug application with priority review for bezuclastinib plus sunitinib (Sutent) in previously treated disease and set a target action date of November 30, 2026.⁴ In the phase 3 Peak study (NCT05208047), patients with GIST that progressed on or were intolerant to imatinib (Gleevec) who received the combination (n = 204) experienced a 50% reduction in the risk of progression or death vs sunitinib alone (n = 209; HR, 0.50; 95% CI, 0.39-0.65; P < .0001), with a median progression-free survival of 16.5 months vs 9.2 months, respectively.⁵

References

1. UTR Therapeutics Inc. announces U.S. FDA orphan drug designation and rare pediatric disease designation for UTRxMYCN M1-14. News release. UTR Therapeutics Inc. September 29, 2026. Accessed October 1, 2026. https://www.prnewswire.com/news-releases/utr-therapeutics-inc-announces-us-fda-orphan-drug-designation-and-rare-pediatric-disease-designation-for-utrxmycn-m1-14-302893199.html
2. SOTIO advances SOT106 with dual FDA designations, further positioning the program as a potential best-in-class ADC for sarcoma. News release. Sotio Biotech. September 23, 2026. Accessed October 1, 2026. https://www.globenewswire.com/news-release/2026/09/23/3367416/0/en/sotio-advances-sot106-with-dual-fda-designations-further-positioning-the-program-as-a-potential-best-in-class-adc-for-sarcoma.html
3. FDA grants fast track designation to Sotio’s SOT106 ADC for soft tissue sarcoma treatment, accelerating clinical development. News release. Sotio Biotech. August 26, 2026. Accessed October 1, 2026. https://sotio.com/news-publications/news/fda-grants-fast-track-designation-to-sotio-s-sot106-adc-for-soft-tissue-sarcoma-treatment-accelerating-clinical-development
4. Cogent Biosciences announces FDA acceptance of new drug application (NDA) with priority review for bezuclastinib in combination with sunitinib for patients with GIST. News release. Cogent Biosciences. May 28, 2026. Accessed October 1, 2026. https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-0
5. Wagner AJ, Trent JC, Tap WD, et al. Primary results of the phase 3 Peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST). J Clin Oncol. 2026;44(suppl 16):11500. doi:10.1200/JCO.2026.44.16_suppl.11500